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Abstract
Advancements in our understanding of the causes and correlates of disease mean that
we are now able to estimate an individual’s level of risk. This, and the ever-increasing
need for healthcare interventions to be cost-effective, has led to calls for the intro-
duction of risk-based screening. Risk-based screening would involve the use of in-
formation about an individual’s risk factors to decide whether or not they should be
eligible for screening, or the frequency with which they should be invited to attend
screening. Evidence is emerging that targeted screening, towards those at higher risk,
can increase the cost-effectiveness of a screening programme. The relationship be-
tween individual risk and the cost-effectiveness of screening an individual is implicitly
recognised in current population screening programmes in the UK. However, the na-
ture of this relationship, and its implications for cost-effectiveness analysis, has not
been presented in the academic literature. In this study we propose that an individ-
ual’s risk of developing a disease has a consistent and quantifiable relationship with
the cost-effectiveness of screening them. We suggest a simple modification to standard
methods of cost-effectiveness analysis that enables the incorporation of individual risk.
Using numerical examples we demonstrate the nature of the relationship between risk
and cost-effectiveness and suggest means of optimising a screening intervention. This
can be done either by defining a minimum level of risk for eligibility or by defining
the optimal recall period for screening. We suggest that methods of decision modelling
could enable such an analysis to be carried out, and that information on individual risk
could be used to optimise the cost-effectiveness of population screening programmes.
Keywords: Risk-based screening; Prevention; Decision modelling; Economic evalua-
tion; Personalised medicine
JEL: I10
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1 Introduction
It is often the case that the earlier a disease is identified, the greater the effect that treat-
ment can have. Screening is a way of identifying those in the early stages of disease, or
those at increased risk of disease, in order that they might be given effective treatment
or engaged in preventative measures. Screening interventions are somewhat unusual in
that they involve a healthcare intervention for an individual who is apparently in good
health. By definition, screening identifies those who can and those who cannot benefit
from treatment. Screening interventions, in themselves, usually confer little or no ben-
efit. As such, assuming we seek to maximise an individual’s health, the extent to which
a screening intervention can be effective depends on the effectiveness of treatment or
care following a positive screen. If an individual is more likely to screen positive it
is more likely that they will receive the intended benefits of screening. Whether or
not an individual benefits from screening is therefore dependent on their likelihood of
screening positive. Little or no health benefit is to be gained in being screened negative.
An individual’s screening outcome is not random; the probability of screening pos-
itive is dependent on a set of (observed or unobserved) risk factors. Advancements in
our understanding of the causes and correlates of disease, and improvements in routine
data collection, mean that it is now possible, in many cases, to estimate an individual’s
risk of developing a disease within a given period of time. Given the simple assertions
outlined thus far we can infer that it is more likely to be cost-effective to screen an
individual at high risk of disease than to screen an individual at low risk of disease. It
is for these reasons that more individualised screening programmes are currently be-
ing proposed by academics and decision-makers alike. Such screening programmes,
which would consider individual risk in their design, will have an important question
to answer: at what level of risk should an individual be referred to screening? In
some cases, where repeated screening is necessary, programmes will also need to dif-
ferentiate screening intervals based on individual risk. Currently there is no generally
accepted way of defining a threshold level of risk for screening eligibility.
This study presents one possible way of defining a threshold level of risk; based
on cost-effectiveness. The framework could also be adapted to consider other maxi-
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mands. We propose that there is a consistent and quantifiable relationship between the
cost-effectiveness of a preventative intervention, such as screening, and an individual’s
estimated level of risk. The framework could be used to inform the design of risk-based
screening programmes, which may be implemented in the future. Section 2 of this pa-
per reviews the background to risk-based screening. Section 3 defines the relationship
between individual risk and the cost-effectiveness of screening, employing numerical
examples and demonstrating the potential for optimisation. Section 4 discusses the
ethical and policy implications of the approach and section 5 concludes.
2 Background
2.1 Screening
Screening involves the attempted identification of asymptomatic disease, for which
early intervention could prevent irreversible effects of disease progression. Effective
screening interventions can reduce the long-term burden of disease in many clinical
areas and can potentially be cost-saving. As with all healthcare interventions, it is
important that screening programmes be cost-effective; they must consider cost of pro-
vision; the expected benefits; and any potential for harm. Designing screening pro-
grammes appropriately – knowing who to screen, how to screen them and how often –
is a difficult undertaking.
In the UK, the National Screening Committee (NSC) was founded to develop a
framework for population screening programmes provided by the National Health Ser-
vice (NHS). A number of population screening programmes have since been devel-
oped. Most national screening programmes in England share a number of character-
istics. Most involve a one-off screening intervention or series of interventions, and no
intervallic recurrence. The majority have no explicit aim besides the early detection
and treatment of disease, with the goal of increasing the effectiveness of treatment and
reducing the burden of disease. All are limited to a particular subset of the popula-
tion, and most are aimed at either pregnant women or newborn babies. Those pro-
grammes designed for adults, such as cancer and abdominal aortic aneurysm screening
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programmes, tend to have a minimum age of eligibility.
One way of ensuring that screening programmes represent good value is to differ-
entiate them based on individuals’ characteristics. At present, eligibility for screening
in publicly-provided programmes is usually defined by a lead risk factor, such as age,
sex or presence of a related disease. It is unusual for publicly-provided screening pro-
grammes to be available to all populations. The nature of screening tends to be ho-
mogeneous for all participants, regardless of their differentiating characteristics. The
policy of screening based on people’s risk seeks to alter this. At its most basic level
it involves defining groups of high risk and low risk individuals and deciding their
eligibility, or offering them different interventions, accordingly. The purpose of this
is to increase the overall cost-effectiveness of screening by reducing the ratio of true
negative to true positive screens, potentially with a reduced overall cost. While such
programmes remain unadopted, it is possible that they will be more widespread in the
future.
2.2 Risk
We use the word risk in the sense of an individual’s hazard rate or hazard function.
That is, an individual with a given set of characteristics, at any moment in time, can be
ascribed a hazard rate representing the probability that an event will occur. Mathemati-
cally this is derived as the limit of a number of events occurring in a given unit of time,
divided by the number of individuals at risk over time. In order to estimate an individ-
ual’s hazard rate we use information collected from relevant hazard ratios, the effect of
which is estimated by treating the log of the hazard rate as a function of baseline hazard
and explanatory variables. Hazard ratios represent the effect on an individual’s hazard
rate of various characteristics; i.e. risk factors. These are calculated using survival
analysis or time-to-event analysis, which involves the use of proportional hazard mod-
els informed by existing data and by expert opinion. Such models are able to estimate
the probability that an individual will develop a given disease within a given period of
time within a given margin of error.
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2.3 Risk-based screening
Current screening programmes implicitly consider risk by offering screens to a limited
section of the population. Age is a risk factor common across most areas of health
and disease. Similarly, men and women tend to have different risk levels for disease,
and some screening programmes are differentiated by sex, or offered to only men or
only women. It is clear that risk is a consideration in the design of NSC screening
programmes in the UK. Current programmes tend to consider only one or two risk
factors when differentiating screening for different individuals. These are usually gen-
eral characteristics such as age or sex. A number of cost-effectiveness analyses of
screening interventions that take account of individuals’ risk factors have been carried
out. Using a Markov model to evaluate colorectal cancer screening, Dan et al find
that selective screening, based primarily on an individual’s age, is more effective than
standardised screening[1]. Similarly, Lansdorp-Vogelaar et al find a small benefit asso-
ciated with individualised colonoscopy screening [2]. Also using decision modelling
methods, Round et al find that the most cost-effective screening method for gestational
diabetes mellitus depends on a woman’s individual risk of disease[3]. Similarly, Aus
et al find that screening intervals for prostate cancer should be individualised based on
prostate-specific antigen levels[4].
Recently there have been calls for individualised screening [5] and assertions that,
in the future, a greater emphasis must be placed on risk-based screening [6]. In the UK,
proposals are in place to implement what we describe here as ‘risk-based screening’;
a screening programme based upon an explicitly estimated level of individual risk,
calculated using data on all known risk factors [7, 8]. The likely outcome of such
studies is that a finite number of risk categories will be defined and screening will
be differentiated depending on into which category an individual falls. However, in
the extreme, screening programmes could be individualised on a per-person basis and
could be very specifically tailored to the individual.
One clinical area where such a programme is being trialled is in screening for di-
abetic retinopathy [8]. In their attempt to optimise screening intervals for diabetic
retinopathy, Aspelund et al develop a model based on a fixed number of diagnoses
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across screening intervals[9]. Their model suggests that optimal screening intervals
range from 6 to 60 months, depending on an individual’s level of risk. Mehlsen et al
adopt a similar method, using a fixed risk margin of 0.5% chance of event [10]. They
use multiple logistic regression to find the optimal screening interval for low-risk dia-
betic retinopathy patients, and find that screening intervals should be extended for most
low-risk individuals. Similarly, Chalk et al find that extending the screening interval
for low-risk individuals is a cost-effective strategy[11]. Davies et al [12] suggest that
simulation methods could be used to stratify individuals based on their risk level, and
that screening intervals could be adjusted accordingly, but the authors believe this to be
impractical.
3 Risk and cost-effectiveness
A relationship between an individual’s level of risk and the cost-effectiveness of screen-
ing them has been implicitly acknowledged by policy-makers and research funding
bodies. However, the nature of this relationship and the ways in which it might be
harnessed have not been investigated. Here we present a stylised example of risk-
based screening using data relating to two screening programmes currently operating
in the UK; the NHS Diabetic Eye Screening Programme and the NHS Bowel Can-
cer Screening Programme. The example is designed such that it could apply to any
basic cost-effectiveness analysis of a screening programme when compared with no
screening. In the case of diabetic retinopathy screening we use reported figures from a
cost-effectiveness analysis of systematic photographic screening compared with oppor-
tunistic screening [13], though we assume that the study compared systematic screen-
ing with no screening for the sake of the demonstration. For bowel cancer we present
figures from a trial of screening for colorectal cancer [14, 15]. The primary outcome
is cost per true positive screen; an outcome relevant, if not paramount, to all screening
programmes.
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Figure 1: Screening pathways
3.1 Defining the relationship
The cost-effectiveness of an intervention is generally presented in the form of an incre-
mental cost-effectiveness ratio (ICER), estimated as:
ICER =
(C1 −C0)
(E1 − E0) (1)
where C1 and E1 represent the cost and effect of intervention ‘1’ and C0 and E0
represent the cost and effect of intervention ‘0’. However, these values are sample
means and are the product of a number of possible prognoses and treatment pathways.
Therefore, the values in equation 1 are expected values; they are defined by probabil-
ities of various events occurring. In traditional trial-based studies these probabilities
may not be observed, while in model-based studies they tend to be explicitly defined.
Whether observed or unobserved, cost-effectiveness estimates are partly defined by a
set of probabilities.
The expected incremental costs and outcomes of a screening intervention, at the in-
dividual level, are dependent on at least two binary probabilities; whether the individual
has a given disease and whether they are screened positive or negative. Allowing for
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false positives and false negatives, this means there will be four possible outcomes for
an individual who is screened and two for an individual who is not. These six possible
pathways are shown in Figure 1.
Therefore, for a given population or individual, ICER calculations in the evaluation
of screening interventions are dependent upon at least three probabilities; the probabil-
ity of a positive disease state, the false negative rate and the false positive rate. For the
screening intervention in Figure 1, the probability of each pathway for the individual,
depending on whether they are screened or not, is:
Prob(1) = r × (1 − β) (2)
Prob(2) = r × β (3)
Prob(3) = (1 − r) × α (4)
Prob(4) = (1 − r) × (1 − α) (5)
Prob(5) = r (6)
Prob(6) = 1 − r (7)
Where r is the probability that the disease (e.g. diabetic eye disease) is present, α
is the false positive rate and β is the false negative rate of the screening intervention.
The probability that an individual has the disease (r) corresponds to the incidence or
prevalence of the disease (depending on the nature of the intervention) in the population
eligible for screening. In trials, r is only observed at the sample level. In modelling
studies, r is usually estimated at the population level. Our primary assertion in this
paper is that, given recent developments in the estimation of risk, r can be estimated
for an individual. This would be in the form of a hazard rate, as described above.
In practice the figures in equations 2–7 may not be known, but they are the under-
lying probabilities in defining an individual’s pathway. The expected incremental cost
of screening (C1 −C0) and the expected incremental effect (E1 − E0) are dependent on
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these probabilities. As such, C1, C0, E1 and E0 are defined as:
C1 =
4∑
k=1
(Prob(k) ×C(k)) (8)
C0 =
6∑
k=5
(Prob(k) ×C(k)) (9)
E1 =
4∑
k=1
(Prob(k) × E(k)) (10)
E0 =
6∑
k=5
(Prob(k) × E(k)) (11)
Where k = 1, 2...6 are the possible pathways shown in Figure 1. Assuming a fixed
cost of screening, and zero cost of no screening, we can estimate the expected costs
and outcomes of screening, as shown in Table 1.
Pathway Probability Cost Expected cost Outcome Expected outcome
Screening
1 r(1 − β) CS (r(1 − β))CS ES (r(1 − β))ES
2 r(β) CS (r(β))CS 0 (r(β))0
3 (1 − r)(α) CS ((1 − r)(α))CS 0 ((1 − r)(α))0
4 (1 − r)(1 − α) CS ((1 − r)(1 − α))CS 0 ((1 − r)(1 − α))0
Total 1 C1 E1
No screening
5 r 0 (r)0 0 (r)(0)
6 (1 − r) 0 (1 − r)0 0 (1 − r)(0)
Total 1 C0 E0
Table 1: Expected costs and outcomes
For the purpose of our demonstration we can now explicitly include ‘r’ in the cal-
culation of the ICER. This is done by substituting the new expressions for probability-
weighted costs and outcomes, shown in Table 1, into a standard ICER calculation
(shown in equation 1) using equations 8–11. This can then be simplified to:
ICER =
CS
(1 − β)rES (12)
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Using these same variables and assumptions, the underlying net monetary benefit
(NMB) expression can be simplified to:
NMB = λ(1 − β)rES −CS (13)
Where λ is the ceiling ratio of willingness to pay for the health outcome. While
ICER and net benefit calculations are not made in this way in practice, these expres-
sions become useful in discussing the relationship between risk and cost-effectiveness.
In equation 12, the denominator represents the expected incremental benefit of screen-
ing an individual of risk r. Here we assume a true positive screen (ES ) to be beneficial
(and of a value of 1) and fixed across risk levels. This means that the relationship be-
tween individual risk (r) and the expected incremental benefit of screening is positive
and linear. Similarly, if we assume that the cost of screening is positive and constant
across risk levels, a higher level of risk (ceteris paribus) will be associated with a lower
ICER. As such, the relationship between an individual’s risk of developing a disease
and the expected cost-effectiveness of screening them must be positive.
Adopting figures relating to existing screening programmes [13, 14, 15], shown in
Table 2, we can estimate cost-effectiveness ratios for individuals at different levels of
risk. In the diabetic retinopathy study, the authors estimate prevalence to be 14.1%, but
that only 4 in 5 people attend screening. For now we assume attendance to be 100%.
Figure 2 shows that the higher the level of individual risk (r), the lower the resulting
cost per positive screen. In this graph we can see that the cost per true positive screen
is extremely sensitive to differences in individual risk when risk is very low. Figure
Diabetic retinopathy Colorectal cancer
α 0.49 0.46
β 0.02 0.02
CS £21 £9.20
ICER £209 per true positive £5290 per true positive
ES 1 1
Table 2: Paramaters for diabetic retinopathy screening [13] and colorectal cancer
screening[14, 15], compared with no screening
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2 only shows risk levels up to 0.1 and ICERs up to £10,000. The curve is almost L-
shaped. This is primarily because we have not accounted for errors in the estimation
of risk. Greater error in the risk engine, or a higher false negative rate, would cause
the curve to flatten. This is because the rate of true positives at lower risk levels would
be lower. The curve will also become flatter with a greater cost of screening, and
become more L-shaped if an intervention is more effective. In this respect the shape of
the curve is an indication of the cost-effectiveness of the intervention. Here we have
assumed true positive screening outcomes to be of equal value for diabetic retinopathy
and for colorectal cancer, so the cheaper intervention — for colorectal cancer — is
more cost-effective.
Figure 2: The relationship between risk and cost-per-outcome
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3.2 Optimisation
In addition to the screening procedure itself, screening interventions can be varied in
two ways; the risk level at which an individual is screened and the frequency with
which screening should take place. This dynamic applies to all screening programmes,
but existing programmes tend to keep these two possible variants fixed. Time and risk
are both continuous variables, infinitely divisible, meaning that we are presented with
an infinite number of possible interventions ranging from constant screening for the
whole asymptomatic population to no screening. For a given individual with a given
level of risk, one (or more) of these infinite possibilities must represent the most cost-
effective intervention. At present there is not a generally accepted way of estimating
this.
Figure 2 highlights that, for a given level of willingness to pay per expected gain,
there will be a corresponding minimum level of risk at and above which it is cost-
effective to screen an individual, and below which the expenditure would not be deemed
cost-effective. Current practice does not estimate this figure. This therefore demon-
strates the potential for optimality in risk-based screening. For a given set of cost and
outcome estimates, and for a given willingness to pay, there is likely to be a level of
risk at which the net benefit of screening becomes positive.
We can use the net benefit approach to estimate whether, at a given level of will-
ingness to pay per true positive screen, it is cost-effective to screen an individual with
a given level of risk. Figure 3 shows the relationship between individual risk and net
benefit. Here, for the purpose of the demonstration, we assume that the willingness to
pay per true positive screen is £500 for diabetic retinopathy and £1000 for colorectal
cancer. As can be seen in equation 13, the slope is defined by the willingness to pay
and the intercept, in our case, is defined by the cost. By solving for r at our assumed
λs, we obtain the minimum level of risk at which individuals should be screened. In
the case of diabetic retinopathy, where λ = £500, the minimum level of individual
risk is 0.0429. In the case of colorectal cancer, where λ = £1000, the minimum level
of individual risk is 0.0094. James et al find that, for systematic diabetic retinopathy
screening, the incremental cost per true positive is £209 [13]. At a willingness to pay
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of £209, for example, it would be cost-effective to screen anybody with a risk level of
0.102 or higher. This assumes that the time period used in the estimation of the hazard
rate matches the screening interval.
Figure 3: The relationship between risk and net benefit
These relationships are intuitive. The higher an individual’s level of risk, the more
likely it is that they will screen positive and therefore benefit as intended from the
screening programme. This means that the expected cost per outcome for an individual
with a high risk is low, while for those at a low risk it may be very high.
As explained above, screening interventions can also be varied in terms of the fre-
quency of their administration. In practice, the question is not one of frequency, but
one of recall period. An individual will only receive a follow-up screen if they are
screened negative at their first screen. In an optimised programme, the time to next
screen would be decided following each negative screening outcome, rather than a
screening frequency being defined at an arbitrary time point. The incremental cost-
effectiveness of subsequent screens can be characterised in the same way as the first;
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the inputs may have changed, but the decision process is the same. As such, the rela-
tionship rationalises to that already discussed.
For some programmes it may be more useful to estimate an optimal recall period
for an individual at a given point in time, rather than to define a minimum level of risk
for population screening. Individual risk is usually estimated in relation to a clinically
relevant period of time. For diabetic retinopathy, the risk estimation may be risk of
developing sight-threatening retinopathy within 1 year. For colorectal cancer the risk
may relate to 10 years or a lifetime. Diabetic retinopathy is one disease area in which
screening is usually recurrent, and we use this example here to demonstrate the defi-
nition of an optimal recall period. In order to establish an optimal recall period, it is
necessary to decide on the lowest practical screening interval. For example, a screening
clinic may have the administrative capacity of recalling individuals on a daily, weekly,
monthly or yearly basis. Maintaining the same assumptions as above, and assuming
that individuals’ hazard ratios are estimated based on a time-at-risk of 1 year and that
screening clinics are capable of recalling individuals for screening on a weekly basis,
we can estimate the recall time at which net monetary benefit becomes positive. This
is simply a matter of estimating the cost-effectiveness of screening an individual at
various periods of recall, accounting for the fact that risk increases in time. It is rea-
sonable to presume that the higher an individual’s level of risk, the more likely it is
to be cost-effective to screen them within a shorter period of time. This is shown in
Figure 4, in which individuals of annual risk 0.01, 0.02 and 0.03 are found to have op-
timal recall periods of 227, 113 and 75 weeks respectively. The optimal recall period,
in terms of cost-effectiveness, can be found by solving for NMB = 0 at any given level
of individual risk. The relationship that this produces is shown in Figure 5.
Decision modelling techniques are routinely used in the evaluation of screening
programmes, and we believe it is these methods that offer the best opportunities for
the incorporation of individual risk data. Modelling methods, and modern computer
software, allow researchers to efficiently carry out thousands of simulations within
short periods of time. Though it is not usually necessary, it is possible to evaluate an
intervention hundreds of times with different hypothetical populations, so long as these
populations are related in some consistent and quantifiable way. Therefore, a model
15
Figure 4: The relationship between recall period and net benefit
Figure 5: The relationship between risk and optimal recall period
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could be designed that evaluated a screening intervention for individuals of any given
risk level. One could estimate whether or not screening was cost-effective, compared
with no screening, for individuals at predicted risk levels from 0 to 1. This would then
enable a researcher to estimate the relationship between risk and cost-effectiveness and
predict the risk level above which screening is cost-effective, and below which it is not.
This, in turn, could inform the delivery of services. We seek to achieve this in future
work for the case of screening for diabetic retinopathy.
4 Discussion
4.1 Policy implications
If, as we suggest, there is a quantifiable relationship between individual risk and cost-
effectiveness, it should arguably be represented and considered in economic evaluations
of preventative interventions. As shown above, the optimally cost-effective screening
interval for an individual is greater the lower their risk, because more regular screening
is associated with higher costs and a lower average probability of a positive screen.
This suggests that screening those with a lower risk less often could increase the cost-
effectiveness of their screening. This has been identified in a number of studies, as
discussed above. In implementing a standardised programme it is very unlikely that
screening will be optimal in terms of cost-effectiveness. The methods we propose
would enable the identification of an optimal screening interval for an individual at any
given risk level, resulting in the optimisation of a risk-based screening programme.
To fully optimise screening in the way described above, a programme of risk-based
screening would need to be implemented. In practice, screening based on individual
risk would require an extra level of intervention; a pre-screen. To some extent this
stage already exists, in that individuals are identified as being a woman over 60, for
example, before being referred to screening. Risk-based screening would require a
more comprehensive and detailed version of this. An individual’s set of characteristics
would need to be used to populate a risk algorithm in order to calculate a level of risk.
This level of risk would then be used to define the appropriate screening intervention
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for this individual, based on cost-effectiveness and other factors. This process would
likely be computerised and could be completed by an individual, at home, or by a
physician. If the relationship between an individual’s level of risk and the expected
cost-effectiveness of screening them can be estimated, then this process would enable
screening to be optimised for each individual.
It’s important to note that, so long as treatment is effective and the risk-engine is
sufficiently accurate, a risk-based screening programme will always be cost-effective at
some level of risk. However, it may be the case that the threshold level of risk identifies
only a very small population. Therefore, it is likely to be important to take account of
the fixed costs of implementing a screening programme and consider that marginal
costs are likely to be decreasing. Such a programme would also require consideration
of accessibility, inclusivity and the communication of risk to patients.
4.2 Ethical issues
To implement a programme such as that described above, one would need to estimate
incremental costs and benefits at the individual level. This is not how economic eval-
uations are currently carried out. However, with the rise of personalised medicine,
it seems likely that such economic evaluations may become necessary. The result-
ing curse of dimensionality will need to be confronted by economists and statisticians
alike. Such an approach could become ethically problematic because evaluations may
indicate that the most cost-effective regime is discriminatory. Efforts are underway
to develop methods that systematically incorporate equity considerations into an eco-
nomic evaluation. Once developed, such methods will be crucial in the evaluation of
risk-based screening and other areas of personalised medicine. However, one must con-
sider that existing screening programmes already discriminate based on age and gender.
It may be that discriminating based on an estimated risk level is more favourable, as it
only indirectly discriminates based on personal characteristics.
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4.3 Limitations
Clearly there are many assumptions in the framework described above, but we believe
that most of these could be relaxed in a probabilistic model-based cost-effectiveness
analysis. Our model assumes that costs, outcomes, sensitivity and specificity are all
constant across risk. There are reasons to believe that all four of these parameters
may differ across individuals of different risk levels. For example, individuals with
a higher risk-level may have a more progressed disease and stand to gain less health
from intervention. In our model, the relationship between risk and the expected benefit
of the screening intervention is linear by definition. Similarly, a screening intervention
may be less sensitive or specific for individuals with a lower risk level. Nevertheless, so
long as these relationships can be estimated they can be built into a model accordingly.
With sufficient observational data one could estimate risk-dependent costs, outcomes,
sensitivities and specificities.
There are a number of important parameters that we have not included in our es-
timations, such as the disutility of screening, the rate of attendance and the predictive
capability of the risk engine. The NSC states that screening should not cause harm.
However, it is clear that a positive screen can lead to harm in the follow-up, as has
been widely reported in relation to breast cancer screening [16]. This is not built into
the model described above. Conversely there may be health benefits associated with
a negative screening outcome. There may also be practical issues relating to screen-
ing partners or children. For example, screening a child, having already screened the
mother, may be associated with a low marginal cost and a high expected benefit. By
using a modelling approach in the way described above, important paramaters could
be incorporated and the relationship with risk would be estimated in the same way.
5 Conclusion
In the future it is possible that screening will cease to be a one-size-fits-all type of
intervention, and that risk-based screening programmes will be rolled-out. This is just
part of a wider movement towards predictive and personalised medicine. Economists
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will need to be able to adapt their methods of evaluation to incorporate new types
of information and interventions of a more variable nature. In this paper we have
described the ways in which this might be done for screening. We have demonstrated
that the cost-effectiveness of a screening intervention could potentially be optimised
based on an individual’s level of risk. and that methods of decision modelling are likely
to enable this. Future work should attempt to observe this relationship and investigate
the role of other variables such as attendance, sensitivity and specificity.
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